EP3373919A4 - Tests und verfahren zur auswahl eines behandlungsplans für eine person mit leukämie - Google Patents

Tests und verfahren zur auswahl eines behandlungsplans für eine person mit leukämie Download PDF

Info

Publication number
EP3373919A4
EP3373919A4 EP16865052.1A EP16865052A EP3373919A4 EP 3373919 A4 EP3373919 A4 EP 3373919A4 EP 16865052 A EP16865052 A EP 16865052A EP 3373919 A4 EP3373919 A4 EP 3373919A4
Authority
EP
European Patent Office
Prior art keywords
leukemia
assays
selecting
subject
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16865052.1A
Other languages
English (en)
French (fr)
Other versions
EP3373919A1 (de
Inventor
Max GORDON
Paul Tardi
Jeffrey TYNER
Lawrence Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Celator Pharmaceuticals Inc
Original Assignee
Oregon Health Science University
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Science University, Celator Pharmaceuticals Inc filed Critical Oregon Health Science University
Publication of EP3373919A1 publication Critical patent/EP3373919A1/de
Publication of EP3373919A4 publication Critical patent/EP3373919A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
EP16865052.1A 2015-11-11 2016-11-10 Tests und verfahren zur auswahl eines behandlungsplans für eine person mit leukämie Pending EP3373919A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254109P 2015-11-11 2015-11-11
PCT/US2016/061444 WO2017083592A1 (en) 2015-11-11 2016-11-10 Assays and methods for selecting a treatment regimen for a subject with leukemia

Publications (2)

Publication Number Publication Date
EP3373919A1 EP3373919A1 (de) 2018-09-19
EP3373919A4 true EP3373919A4 (de) 2019-06-19

Family

ID=58695625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16865052.1A Pending EP3373919A4 (de) 2015-11-11 2016-11-10 Tests und verfahren zur auswahl eines behandlungsplans für eine person mit leukämie

Country Status (15)

Country Link
US (3) US10927418B2 (de)
EP (1) EP3373919A4 (de)
JP (2) JP6976941B2 (de)
KR (1) KR20180108572A (de)
CN (2) CN108778260A (de)
AU (2) AU2016353163B2 (de)
BR (1) BR112018009463A8 (de)
CA (2) CA3005076C (de)
CO (1) CO2018005846A2 (de)
HK (1) HK1258724A1 (de)
IL (2) IL292080A (de)
MX (1) MX2018005771A (de)
MY (1) MY193531A (de)
SG (2) SG11201804020YA (de)
WO (1) WO2017083592A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CA3114002A1 (en) * 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
WO2020102595A1 (en) * 2018-11-14 2020-05-22 Dana-Farber Cancer Institute, Inc. Determining treatment response in single cells
CN111870600B (zh) * 2020-07-13 2022-04-15 中南大学湘雅二医院 索拉非尼、瑞戈非尼及其类似物或衍生物的新应用
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407169A1 (de) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Kombinationsformulierungen aus Anthracyclinwirkstoffen und Cytidinanaloga
PL2120568T3 (pl) 2007-02-16 2018-03-30 Celator Pharmaceuticals, Inc. Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
TWI546537B (zh) * 2009-05-19 2016-08-21 維維亞生技公司 提供針對血液腫瘤之體外個人化藥物測試之方法
US20120010229A1 (en) * 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
JP6133308B2 (ja) * 2011-10-21 2017-05-24 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム
WO2014087018A1 (en) * 2012-12-07 2014-06-12 Evotec (München) Gmbh Markers for responsiveness to an inhibitor of flt3
EP3191126B1 (de) * 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CA3114002A1 (en) * 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EDWARDS ET AL.: "Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation | Blood Journal", 2 December 2016 (2016-12-02), XP055586480, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/128/22/5124?sso-checked=true> [retrieved on 20190507] *
GABRIELA MOTYCKOVA ET AL: "Treatment of Elderly Acute Myeloid Leukemia Patients", CURRENT TREATMENT OPTIONS IN ONCOLOGY, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 12, no. 4, 7 September 2011 (2011-09-07), pages 341 - 353, XP019976971, ISSN: 1534-6277, DOI: 10.1007/S11864-011-0162-4 *
JEFFREY E LANCET ET AL: "Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vscytarabine/daunorubicin in older adults with untreated AML", 31 March 2014 (2014-03-31), XP055586678, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/bloodjournal/123/21/3239.full.pdf> [retrieved on 20190508], DOI: 10.1182/blood-2013-12- *
JORGE E. CORTES ET AL: "Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML : CPX-351 in AML Patients in First Relapse", CANCER., vol. 121, no. 2, 15 September 2014 (2014-09-15), US, pages 234 - 242, XP055586671, ISSN: 0008-543X, DOI: 10.1002/cncr.28974 *
MULTILEARNING GROUP INC.: "CPX-351 TREATMENT OF PREVIOUSLY UNTREATED OLDER AML PATIENTS WITH.... EHA Learning Center. Lancet J. Jun 11 2016; 135258", 11 June 2016 (2016-06-11), XP055586905, Retrieved from the Internet <URL:https://learningcenter.ehaweb.org/eha/2016/21st/135258/jeffrey.lancet.cpx-351.treatment.of.previously.untreated.older.aml.patients.html?f=listing=0*browseby=8*sortby=1*search=cpx> [retrieved on 20190508] *

Also Published As

Publication number Publication date
US20230279503A1 (en) 2023-09-07
AU2022291559A1 (en) 2023-02-02
BR112018009463A2 (pt) 2018-11-06
US20210246512A1 (en) 2021-08-12
KR20180108572A (ko) 2018-10-04
US10927418B2 (en) 2021-02-23
US20180327854A1 (en) 2018-11-15
JP6976941B2 (ja) 2021-12-08
CN115414376A (zh) 2022-12-02
CA3005076C (en) 2024-01-02
HK1258724A1 (zh) 2019-11-15
AU2016353163A1 (en) 2018-06-07
MX2018005771A (es) 2019-03-14
AU2016353163B2 (en) 2022-09-29
CN108778260A (zh) 2018-11-09
US11746386B2 (en) 2023-09-05
IL259271B (en) 2022-05-01
SG10202112699UA (en) 2021-12-30
SG11201804020YA (en) 2018-06-28
CA3219061A1 (en) 2017-05-18
CO2018005846A2 (es) 2018-08-21
WO2017083592A1 (en) 2017-05-18
EP3373919A1 (de) 2018-09-19
CA3005076A1 (en) 2017-05-18
JP2018535975A (ja) 2018-12-06
BR112018009463A8 (pt) 2019-02-26
IL292080A (en) 2022-06-01
JP2022024031A (ja) 2022-02-08
RU2018121249A3 (de) 2020-03-17
IL259271A (en) 2018-07-31
MY193531A (en) 2022-10-18
RU2018121249A (ru) 2019-12-17

Similar Documents

Publication Publication Date Title
ZA201704117B (en) Cd47 antibodies, methods, and uses
EP3374114A4 (de) Werkbank
EP3167198A4 (de) Platte mit einem schieber
EP3359095A4 (de) Automatisierte hand
EP3282954A4 (de) Zange mit magnetisch gesteuerter positionierung
EP3230463A4 (de) Schnelle vorbehandlung
EP3268903A4 (de) Vorrichtung mit mehreren identifikatoren
EP3286549A4 (de) Biosensor
IL241156A0 (en) Tests and methods for choosing treatment methods for those with depression
EP3195964A4 (de) Werkzeugmaschine mit werkzeugrücksetzung
EP3093668A4 (de) Automatisierter analysator
EP3125726A4 (de) Gemeinsame armlehne
HK1258724A1 (zh) 選擇白血病對象的治療方案的分析和方法
EP3245891A4 (de) Reissverschluss
AU201613057S (en) Luggage with handle down
EP3176587A4 (de) Automatisierter analysator
EP3364189A4 (de) Immunochromatografisches teststück
EP3387414A4 (de) Biosensor
EP3294647A4 (de) Entstapler mit geneigten rollen
EP3114585A4 (de) Querindizieren mit grouplets
EP3111099A4 (de) Befestigungsmittel
EP3221548A4 (de) Spülungsansatzstück mit aktivierungsmechanismus und verfahren dafür
EP3463755A4 (de) Werkzeug mit werkzeugelementen
HK1226113B (zh) 門扇與用於門扇的面板和面板工具
EP3377410A4 (de) Beutel mit ausschnitten

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20190514BHEP

Ipc: A61K 31/00 20060101AFI20190514BHEP

Ipc: A61P 35/02 20060101ALI20190514BHEP

Ipc: C12Q 1/68 20180101ALI20190514BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258724

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200429

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230527